High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.
about
StreptomeDB: a resource for natural compounds isolated from Streptomyces speciesDaptomycin: an evidence-based review of its role in the treatment of Gram-positive infectionsHeteroresistance to Fosfomycin Is Predominant in Streptococcus pneumoniae and Depends on the murA1 GeneStaphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial.Characterization of a novel two-component regulatory system, HptRS, the regulator for the hexose phosphate transport system in Staphylococcus aureusHigh-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE)FosfomycinFosfomycin: Resurgence of an old companion.A current perspective on daptomycin for the clinical microbiologist.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.High activity of Fosfomycin and Rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model.Current use of daptomycin in cardiac surgery and postoperative intensive care.Current and prospective treatments for multidrug-resistant gram-positive infections.New pharmacological treatments for methicillin-resistant Staphylococcus aureus infections.Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.Daptomycin plus fosfomycin, a synergistic combination in experimental implant-associated osteomyelitis due to methicillin-resistant Staphylococcus aureus in rats.Efficacy of fosfomycin compared to vancomycin in treatment of implant-associated chronic methicillin-resistant Staphylococcus aureus osteomyelitis in rats.Intravenous Fosfomycin for the treatment of hospitalized patients with serious infections.2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the EurActivities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum-β-lactamase-producing Escherichia coli in a foreign-body infection model.Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureusDaptomycin In Vitro Activity against Methicillin-Resistant Staphylococcus aureus Is Enhanced by d-Cycloserine in a Mechanism Associated with a Decrease in Cell Surface Charge.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.The Combination of Daptomycin plus Fosfomycin has Synergistic, Potent and Rapid Bactericidal Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) in a Rabbit Model of Experimental Endocarditis (EE).
P2860
Q24595628-C7ADC889-A788-4B0C-B003-0E8E8151BEBFQ26752922-749A45A0-60BB-45F5-B472-D134C1A12AFBQ27677278-C4673AF6-E50F-47ED-A2E1-CAC2DE526897Q34478074-1C9FFBFD-A7A7-4C2E-A69A-0D235DCC4FB3Q35169018-39865303-FA69-4D7B-B397-4A1419710722Q35179800-F7BE1B32-8EFE-4F4E-9732-584D62D26A59Q35187562-315C217A-D79A-4E44-B525-C0E4226490D2Q35848781-C3EF1275-BBBC-46F1-A1BD-8DB7BE7002AEQ36073392-8E28F2D7-75A6-4AE1-BE71-86F298A2C890Q36675246-1AD21B43-BBE5-43C9-A4E0-6487BC72460FQ36803694-284FAC0B-EA77-4204-A29A-A276CB1047B8Q37263289-25C04494-D010-4B19-96E1-BEDFE210A3C9Q37287661-AE621435-3750-4896-A4E9-5CFEF5A16E5FQ37712972-371816F4-855C-4CDB-8345-BDC1C3CE4B33Q38086339-7203EC28-E099-4994-8D09-FC2573E41A1EQ38123255-CABA6BFF-A60F-47B3-B5A5-0BA870E9C0D7Q38179460-162CBCFD-53F2-4BAB-A710-BC3942C1D7A6Q38208281-1EB50529-560E-439B-80C6-EA9128478627Q39182290-F28FE9F1-0593-4332-AE1A-7B023F144810Q39361363-61A5DF31-7CB5-409B-A2A5-64CFF771231AQ40049542-C18CD3DE-CCA3-4D5B-95F3-7667BA9C92DAQ41026009-EC822109-C857-46B6-A52F-30A680EA847EQ41453531-1954BD27-E1EA-43F9-8F2E-220D6883785CQ42529961-2B2F988A-FBF7-4574-B3BD-7672ED79903BQ42573041-BC907718-90F7-41E4-9E7A-931067EA9E7BQ47634145-F410FEE5-EEE3-400D-B5F8-6688B0F63FEBQ53699196-B18C7DE2-179A-4C80-999D-D352F5226269
P2860
High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@ast
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@en
type
label
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@ast
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@en
prefLabel
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@ast
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@en
P2093
P2860
P50
P356
P1476
High-dose daptomycin plus fosf ...... ylococcus aureus endocarditis.
@en
P2093
Ana Del Río
Asuncion Moreno
Carlos A Mestres
Cristina Garcia de la Mària
Hospital Clinic Experimental Endocarditis Study Group
José M Entenza
José M Miró
Juan M Pericàs
Manuel Almela
Maria Velasco
P2860
P304
P356
10.1128/AAC.06449-11
P407
P577
2012-05-29T00:00:00Z